Logo image of PHH

PARK HA BIOLOGICAL TECHNOLOG (PHH) Stock Fundamental Analysis

NASDAQ:PHH - Nasdaq - KYG6925R1020 - Common Stock - Currency: USD

14.53  -0.03 (-0.21%)

After market: 14.85 +0.32 (+2.2%)

Fundamental Rating

4

Overall PHH gets a fundamental rating of 4 out of 10. We evaluated PHH against 121 industry peers in the Specialty Retail industry. PHH is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. PHH does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

In the past year PHH has reported negative net income.
PHH had a positive operating cash flow in the past year.
PHH Yearly Net Income VS EBIT VS OCF VS FCFPHH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 500K 1M

1.2 Ratios

PHH has a Return On Assets of 15.52%. This is amongst the best in the industry. PHH outperforms 91.74% of its industry peers.
The Return On Equity of PHH (31.78%) is better than 85.95% of its industry peers.
PHH has a better Return On Invested Capital (33.71%) than 96.69% of its industry peers.
The Average Return On Invested Capital over the past 3 years for PHH is significantly above the industry average of 12.74%.
The 3 year average ROIC (65.68%) for PHH is well above the current ROIC(33.71%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA 15.52%
ROE 31.78%
ROIC 33.71%
ROA(3y)20.25%
ROA(5y)N/A
ROE(3y)81.07%
ROE(5y)N/A
ROIC(3y)65.68%
ROIC(5y)N/A
PHH Yearly ROA, ROE, ROICPHH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 20 40 60 80 100

1.3 Margins

The Profit Margin of PHH (20.09%) is better than 99.17% of its industry peers.
With an excellent Operating Margin value of 33.32%, PHH belongs to the best of the industry, outperforming 99.17% of the companies in the same industry.
With an excellent Gross Margin value of 91.80%, PHH belongs to the best of the industry, outperforming 98.35% of the companies in the same industry.
Industry RankSector Rank
OM 33.32%
PM (TTM) 20.09%
GM 91.8%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PHH Yearly Profit, Operating, Gross MarginsPHH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 20 40 60 80

More info and screens

9

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), PHH is creating value.
Compared to 1 year ago, PHH has less shares outstanding
There is no outstanding debt for PHH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PHH Yearly Shares OutstandingPHH Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 5M 10M 15M 20M 25M
PHH Yearly Total Debt VS Total AssetsPHH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 1M 2M 3M

2.2 Solvency

An Altman-Z score of 1049.60 indicates that PHH is not in any danger for bankruptcy at the moment.
PHH has a better Altman-Z score (1049.60) than 100.00% of its industry peers.
PHH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 1049.6
ROIC/WACC4.11
WACC8.2%
PHH Yearly LT Debt VS Equity VS FCFPHH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 500K 1M 1.5M

2.3 Liquidity

PHH has a Current Ratio of 1.87. This is a normal value and indicates that PHH is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.87, PHH belongs to the top of the industry, outperforming 80.17% of the companies in the same industry.
PHH has a Quick Ratio of 1.82. This is a normal value and indicates that PHH is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.82, PHH belongs to the top of the industry, outperforming 86.78% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.87
Quick Ratio 1.82
PHH Yearly Current Assets VS Current LiabilitesPHH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 500K 1M 1.5M 2M 2.5M

More info and screens

0

3. Growth

3.1 Past

PHH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -41.23%.
Looking at the last year, PHH shows a decrease in Revenue. The Revenue has decreased by -3.14% in the last year.
EPS 1Y (TTM)-41.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-41.23%
Revenue 1Y (TTM)-3.14%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-3.14%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PHH Yearly Revenue VS EstimatesPHH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 500K 1M 1.5M 2M

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

Industry RankSector Rank
PE N/A
Fwd PE N/A
PHH Price Earnings VS Forward Price EarningsPHH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, PHH is valued a bit more expensive than the industry average as 73.55% of the companies are valued more cheaply.
60.33% of the companies in the same industry are cheaper than PHH, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 3146.59
EV/EBITDA 3371.39
PHH Per share dataPHH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0 0.01 0.01 0.01

4.3 Compensation for Growth

The decent profitability rating of PHH may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

PHH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PARK HA BIOLOGICAL TECHNOLOG

NASDAQ:PHH (5/23/2025, 8:46:29 PM)

After market: 14.85 +0.32 (+2.2%)

14.53

-0.03 (-0.21%)

Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Discretionary Distribution & Retail
GICS IndustrySpecialty Retail
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.3%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner Change0%
Market Cap383.16M
AnalystsN/A
Price TargetN/A
Short Float %2.16%
Short Ratio0.24
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1155.78
P/FCF 3146.59
P/OCF 2866.17
P/B 1827.87
P/tB 1837.14
EV/EBITDA 3371.39
EPS(TTM)0
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0
FCFY0.03%
OCF(TTM)0.01
OCFY0.03%
SpS0.01
BVpS0.01
TBVpS0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 15.52%
ROE 31.78%
ROCE 50.92%
ROIC 33.71%
ROICexc 51.97%
ROICexgc 52.36%
OM 33.32%
PM (TTM) 20.09%
GM 91.8%
FCFM 36.73%
ROA(3y)20.25%
ROA(5y)N/A
ROE(3y)81.07%
ROE(5y)N/A
ROIC(3y)65.68%
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)99.2%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.77
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 377.09%
Cap/Sales 3.59%
Interest Coverage 250
Cash Conversion 117.65%
Profit Quality 182.8%
Current Ratio 1.87
Quick Ratio 1.82
Altman-Z 1049.6
F-Score6
WACC8.2%
ROIC/WACC4.11
Cap/Depr(3y)176.35%
Cap/Depr(5y)N/A
Cap/Sales(3y)1.71%
Cap/Sales(5y)N/A
Profit Quality(3y)314.24%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-41.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-41.23%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-3.14%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-3.14%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-32.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y742.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y659.29%
OCF growth 3YN/A
OCF growth 5YN/A